Circulating vaspin levels and nutritional status and insulin resistance in polycystic ovary syndrome
, 8
Abstract
Objectives: The study aimed to assess the associations between circulating vaspin levels and nutritional status (assessed
on tha basis of BMI) as well as insulin resistance in PCOS.
Material and methods: Eighty-seven PCOS women, 48 obese and 39 normal weight, were enrolled in the cross-sectional
study. Seventy-two Non-PCOS women, 41 obese and 31 normal weight, constituted a control group. Body mass, height and
waist circumference as well as body composition by bioimpedance were measured. In the morning (16h after the last meal)
we determined: serum glucose, insulin, androgens, gonadotropin (LH, FSH) and sex hormone-binding globulin (SHBG) as
well as plasma vaspin levels. Standard HOMA-IR formula was used to assess insulin resistance (IR).
Results: Plasma vaspin levels were significantly lower in PCOS, both normal weight and obese, than in Non-PCOS
groups. Vaspin levels were similar in normal weight and obese PCOS subgroups. There was no association between plasma
vaspin levels and anthropometric parameters in PCOS group. While in Non-PCOS group a negative correlation between
plasma vaspin levels and body mass (r = –0.26; p < 0.05) was found. We did not observe correlations between plasma vaspin
levels and serum glucose and insulin concentrations as well as HOMA-IR values, however, in multivariable, stepwise backward
regression waist circumference and HOMA-IR values explained 18.0% of plasma vaspin levels variability in the study subjects.
Conclusions: PCOS occurrence is associated with decreased vaspin levels. The influence of nutritional status on vaspin level
observed in Non-PCOS is abolished in PCOS women, possibly by more severe insulin resistance.
Keywords: vaspininsulin resistancenutritional statusPCOS
References
- Hida K, Wada J, Eguchi J, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A. 2005; 102(30): 10610–10615.
- Klöting N, Berndt J, Kralisch S, et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun. 2006; 339(1): 430–436.
- Körner A, Neef M, Friebe D, et al. Vaspin is related to gender, puberty and deteriorating insulin sensitivity in children. Int J Obes (Lond). 2011; 35(4): 578–586.
- Klöting N, Kovacs P, Kern M, et al. Central vaspin administration acutely reduces food intake and has sustained blood glucose-lowering effects. Diabetologia. 2011; 54(7): 1819–1823.
- Meyer-Hoffert U. Reddish, scaly, and itchy: how proteases and their inhibitors contribute to inflammatory skin diseases. Arch Immunol Ther Exp (Warsz). 2009; 57(5): 345–354.
- Wada J. Vaspin: a novel serpin with insulin-sensitizing effects. Expert Opin Investig Drugs. 2008; 17(3): 327–333.
- González CR, Caminos JE, Vázquez MJ, et al. Regulation of visceral adipose tissue-derived serine protease inhibitor by nutritional status, metformin, gender and pituitary factors in rat white adipose tissue. J Physiol. 2009; 587(Pt 14): 3741–3750.
- Youn BS, Klöting N, Kratzsch J, et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes. 2008; 57(2): 372–377.
- Aust G, Richter O, Rohm S, et al. Vaspin serum concentrations in patients with carotid stenosis. Atherosclerosis. 2009; 204(1): 262–266.
- Handisurya A, Riedl M, Vila G, et al. Serum vaspin concentrations in relation to insulin sensitivity following RYGB-induced weight loss. Obes Surg. 2010; 20(2): 198–203.
- Zvonic S, Lefevre M, Kilroy G, et al. Secretome of primary cultures of human adipose-derived stem cells: modulation of serpins by adipogenesis. Mol Cell Proteomics. 2007; 6(1): 18–28.
- Suleymanoglu S, Tascilar E, Pirgon O, et al. Vaspin and its correlation with insulin sensitivity indices in obese children. Diabetes Res Clin Pract. 2009; 84(3): 325–328.
- Gulcelik NE, Karakaya J, Gedik A, et al. Serum vaspin levels in type 2 diabetic women in relation to microvascular complications. Eur J Endocrinol. 2009; 160(1): 65–70.
- Tan BK, Heutling D, Chen J, et al. Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes. 2008; 57(6): 1501–1507.
- Cakal E, Ustun Y, Engin-Ustun Y, et al. Serum vaspin and C-reactive protein levels in women with polycystic ovaries and polycystic ovary syndrome. Gynecol Endocrinol. 2011; 27(7): 491–495.
- Koiou E, Tziomalos K, Dinas K, et al. The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome. Endocr J. 2011; 58(4): 237–246.
- Koiou E, Dinas K, Tziomalos K, et al. The phenotypes of polycystic ovary syndrome defined by the 1990 diagnostic criteria are associated with higher serum vaspin levels than the phenotypes introduced by the 2003 criteria. Obes Facts. 2011; 4(2): 145–150.
- Cekmez F, Cekmez Y, Pirgon O, et al. Evaluation of new adipocytokines and insulin resistance in adolescents with polycystic ovary syndrome. Eur Cytokine Netw. 2011; 22(1): 32–37.
- Akbarzadeh S, Ghasemi S, Kalantarhormozi M, et al. Relationship among plasma adipokines, insulin and androgens level as well as biochemical glycemic and lipidemic markers with incidence of PCOS in women with normal BMI. Gynecol Endocrinol. 2012; 28(7): 521–524.
- Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19(1): 41–47.
